Clinical Trial Update: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of plitidepsin in relapsed or refractory angioimmunoblastic T-cell lymphoma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Lymphoma

Drugs mentioned

• Plitidepsin (plitidepsin)

Snippet

Sponsor: PharmaMar | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-10-14